JP2019516790A5 - - Google Patents

Download PDF

Info

Publication number
JP2019516790A5
JP2019516790A5 JP2019510737A JP2019510737A JP2019516790A5 JP 2019516790 A5 JP2019516790 A5 JP 2019516790A5 JP 2019510737 A JP2019510737 A JP 2019510737A JP 2019510737 A JP2019510737 A JP 2019510737A JP 2019516790 A5 JP2019516790 A5 JP 2019516790A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
cyclopentyl
amino
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019510737A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019516790A (ja
JP6927548B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2017/083162 external-priority patent/WO2017193872A1/en
Publication of JP2019516790A publication Critical patent/JP2019516790A/ja
Publication of JP2019516790A5 publication Critical patent/JP2019516790A5/ja
Application granted granted Critical
Publication of JP6927548B2 publication Critical patent/JP6927548B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019510737A 2016-05-07 2017-05-05 ある種のタンパク質キナーゼ阻害剤 Active JP6927548B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662333165P 2016-05-07 2016-05-07
US62/333,165 2016-05-07
PCT/CN2017/083162 WO2017193872A1 (en) 2016-05-07 2017-05-05 Certain protein kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2019516790A JP2019516790A (ja) 2019-06-20
JP2019516790A5 true JP2019516790A5 (cg-RX-API-DMAC7.html) 2020-04-09
JP6927548B2 JP6927548B2 (ja) 2021-09-01

Family

ID=60266275

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019510737A Active JP6927548B2 (ja) 2016-05-07 2017-05-05 ある種のタンパク質キナーゼ阻害剤

Country Status (13)

Country Link
US (1) US10835535B2 (cg-RX-API-DMAC7.html)
EP (1) EP3452484B1 (cg-RX-API-DMAC7.html)
JP (1) JP6927548B2 (cg-RX-API-DMAC7.html)
KR (1) KR102374033B1 (cg-RX-API-DMAC7.html)
CN (1) CN109153686B (cg-RX-API-DMAC7.html)
AU (1) AU2017262155B2 (cg-RX-API-DMAC7.html)
DK (1) DK3452484T3 (cg-RX-API-DMAC7.html)
ES (1) ES2954148T3 (cg-RX-API-DMAC7.html)
MX (1) MX387648B (cg-RX-API-DMAC7.html)
RU (1) RU2738837C2 (cg-RX-API-DMAC7.html)
TW (1) TWI752026B (cg-RX-API-DMAC7.html)
WO (1) WO2017193872A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201808238B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019161224A1 (en) 2018-02-15 2019-08-22 GiraFpharma LLC Heterocyclic compounds as kinase inhibitors
WO2022113003A1 (en) 2020-11-27 2022-06-02 Rhizen Pharmaceuticals Ag Cdk inhibitors
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors
CN116836177A (zh) * 2022-09-28 2023-10-03 锦州奥鸿药业有限责任公司 一种蛋白激酶抑制剂的枸橼酸盐、其晶型、制备方法和用途
WO2025085360A1 (en) 2023-10-16 2025-04-24 The Board Of Regents Of The University Of Oklahoma Heteroarotinoids and/or cdk4/6 inhibitors for treating human papillomavirus (hpv)-induced dysplasias, warts, and cancer in hpv-infected subjects
US20260209246A1 (en) * 2025-01-23 2026-07-23 Incyte Corporation Furanyl or thienyl pyrimidines as cdk4 inhibitors

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
US6277985B1 (en) 1995-09-15 2001-08-21 Pharmacia & Upjohn Company Aminoaryl oxazolidinone N-oxides
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
ES2294494T3 (es) 2004-04-19 2008-04-01 Symed Labs Limited Un nuevo procedimiento para la preparacion de linezolid y compuestos relacionados.
EP1768967B1 (en) 2004-07-20 2009-04-22 Symed Labs Limited Novel intermediates for linezolid and related compounds
JP2008514702A (ja) 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド 新規シクロスポリン類似体およびそれらの薬学的使用
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
MX2009008465A (es) 2007-02-15 2009-08-20 Hoffmann La Roche Nuevas 2-aminooxazolinas como ligandos de taar1.
US7528131B2 (en) 2007-04-19 2009-05-05 Concert Pharmaceuticals Inc. Substituted morpholinyl compounds
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
DE102007038251A1 (de) 2007-08-13 2009-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neues Herstellverfahren
US20090131485A1 (en) 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
WO2009045476A1 (en) 2007-10-02 2009-04-09 Concert Pharmaceuticals, Inc. Pyrimidinedione derivatives
EP2212298B1 (en) 2007-10-18 2013-03-27 Concert Pharmaceuticals Inc. Deuterated etravirine
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
WO2009055006A1 (en) 2007-10-26 2009-04-30 Concert Pharmaceuticals, Inc. Deuterated darunavir
SI2215094T1 (sl) 2007-11-15 2016-05-31 Ym Biosciences Australia Pty Ltd N vsebujoče heterociklične spojine
AU2009284098B2 (en) 2008-08-22 2012-03-29 Astex Therapeutics Ltd. Pyrrolopyrimidine compounds as CDK inhibitors
UY33227A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
AR083797A1 (es) 2010-11-10 2013-03-20 Novartis Ag Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
FR2988722B1 (fr) * 2012-04-03 2014-05-09 Sanofi Sa Nouveaux derives de thienopyrimidines, leurs procedes de preparation et leurs utilisations therapeutiques
RU2671494C2 (ru) * 2014-05-28 2018-11-01 Шанхай Фокон Фармасьютикал Ко., Лтд Некоторые ингибиторы протеинкиназы
CN105294737B (zh) * 2014-07-26 2019-02-12 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途

Similar Documents

Publication Publication Date Title
RU2018143284A (ru) Некоторые ингибиторы протеинкиназы
JP2017519781A5 (cg-RX-API-DMAC7.html)
AU2018256624A1 (en) JAK2 and ALK2 inhibitors and methods for their use
JP2017525668A5 (cg-RX-API-DMAC7.html)
JP2013528204A5 (cg-RX-API-DMAC7.html)
NZ627709A (en) Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
IL279800B2 (en) Selective allosteric inhibitors of epidermal growth factor receptor mutants, pharmaceutical preparations containing them and their use
JP2017502940A5 (cg-RX-API-DMAC7.html)
JP2017514830A5 (cg-RX-API-DMAC7.html)
JP2014504622A5 (cg-RX-API-DMAC7.html)
CA2474738A1 (en) N-phenyl-2-pyrimidine-amine derivatives
EP4104837A3 (en) Heterocyclic compounds as ret kinase inhibitors
JP2012501312A5 (cg-RX-API-DMAC7.html)
JP2019512535A5 (cg-RX-API-DMAC7.html)
MX2021000095A (es) Derivados de aril-n-arilo para el tratamiento de una infeccion por virus de acido ribonucleico (arn).
HRP20121069T1 (hr) Supstituirani derivati amida kao inhibitori protein kinaze
HRP20181008T1 (hr) Terapeutski aktivni pirazolo-pirimidin derivati
JP2013529196A5 (cg-RX-API-DMAC7.html)
RU2016110096A (ru) Новое хинолин-замещенное соединение
RU2016134751A (ru) Соединения
JP2012513416A5 (cg-RX-API-DMAC7.html)
JP2016028076A5 (cg-RX-API-DMAC7.html)
PH12017501699A1 (en) Fused bicyclic heteroaryl derivatives having activity as phd inhibitors
JP2014500296A5 (cg-RX-API-DMAC7.html)
JP2019505594A5 (cg-RX-API-DMAC7.html)